EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 321 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Additional Extensions of Indications for Pembrolizumab October 7, 2024 Experimental mRNA Vaccine Hints at Potential Against Glioblastoma June 11, 2024 What to Know About 3 Common Misconceptions Around Food and Cancer... April 25, 2023 Study Suggests Some Arthritis Drugs May Actually Stop the Spread of... November 26, 2019 Load more HOT NEWS Ovarian Cancer Studies Aim to Reduce Racial Disparities, Improve Outcomes Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... News digest – calorie guidelines, reduced lung cancer referrals and COVID-19’s... Finding New Uses for Targeted Therapies for Cancer: Updates from the...
